Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar 8;6(5):1580-1584.
doi: 10.1182/bloodadvances.2021006655.

SARS-CoV-2-neutralizing antibody treatment in patients with COVID-19 and immunodeficiency due to B-cell non-Hodgkin lymphoma

Jakob J Malin  1   2 , Veronica Di Cristanziano  3 , Carola Horn  1 , Elisabeth Pracht  1 , Jorge Garcia Borrega  1 , Eva Heger  3 , Elena Knops  3   4 , Rolf Kaiser  3 , Boris Böll  1 , Clara Lehmann  1   4 , Norma Jung  1 , Peter Borchmann  1 , Gerd Fätkenheuer  1 , Florian Klein  3   4 , Michael Hallek  1 , Jan Rybniker  1   2   4
Affiliations

SARS-CoV-2-neutralizing antibody treatment in patients with COVID-19 and immunodeficiency due to B-cell non-Hodgkin lymphoma

Jakob J Malin et al. Blood Adv. .
No abstract available

PubMed Disclaimer

Figures

None
Graphical abstract
Figure 1.
Figure 1.
Evolution of maximum daily body temperature, CRP, and SARS-CoV-2 viral load, before and after treatment with nmAbs. Evolution of temperature (A) and C-reactive protein (B) in each patient from 2 days before (day −2) to 5 days after (day 5) nmAb treatment (day 0). SARS-CoV-2 RNA was determined by quantitative RT-PCR, and cycle threshold values were translated to viral concentrations based on the respective PCR core standards. Viral loads obtained from respiratory tract specimens (C) and blood (D) before and after nmAb treatment are presented cumulatively and represent samples that were taken from 2 days before until midday at the day of nmAb treatment (pre-treatment) or from days 1 to 5 after treatment (post-treatment). If several samples were taken during these time periods the median from all available assessments is shown for each patient. Patient F is not included in panel C, as only samples obtained from BAL were positive and no subsequent assessments were performed. CRP, C-reactive protein; FU, follow-up; ND, not detected.
See this image and copyright information in PMC

References

    1. Israelow B, Mao T, Klein J, et al. . Adaptive immune determinants of viral clearance and protection in mouse models of SARS-CoV-2. Sci Immunol 2021;6(64):eabl4509. - PMC - PubMed
    1. Bergwerk M, Gonen T, Lustig Y, et al. . Covid-19 breakthrough infections in vaccinated health care workers. N Engl J Med. 2021;385(16):1474-1484. - PMC - PubMed
    1. Brosh-Nissimov T, Orenbuch-Harroch E, Chowers M, et al. . BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully vaccinated hospitalized COVID-19 patients in Israel. Clin Microbiol Infect. 2021;27(11):1652-1657. - PMC - PubMed
    1. Helleberg M, Niemann CU, Moestrup KS, et al. . Persistent COVID-19 in an immunocompromised patient temporarily responsive to two courses of remdesivir therapy. J Infect Dis. 2020;222(7):1103-1107. - PMC - PubMed
    1. Avanzato VA, Matson MJ, Seifert SN, et al. . Case study: prolonged infectious SARS-CoV-2 shedding from an asymptomatic immunocompromised individual with cancer. Cell. 2020;183(7):1901-1912.e1909. - PMC - PubMed